Cargando…

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

BACKGROUND: To study the molecular mechanism regulating sensitivity to MEK inhibition in pancreatic cancer cell lines. METHODS: A growth inhibition assay determined sensitivity to MEK162 in a panel of 29 pancreatic cancer cell lines. For the same panel, KRAS mutational status and copy-number variati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamidi, H, Lu, M, Chau, K, Anderson, L, Fejzo, M, Ginther, C, Linnartz, R, Zubel, A, Slamon, D J, Finn, R S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453732/ https://www.ncbi.nlm.nih.gov/pubmed/25167228 http://dx.doi.org/10.1038/bjc.2014.475

Ejemplares similares

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

KIF15 promotes pancreatic cancer proliferation via the MEK–ERK signalling pathway
por: Wang, Jie, et al.
Publicado: (2017)

Genomic copy number and expression patterns in testicular germ cell tumours
por: McIntyre, A, et al.
Publicado: (2007)

Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas
por: Seo, A N, et al.
Publicado: (2014)

DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure
por: Kettunen, E, et al.
Publicado: (2009)

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
por: Lee, H E, et al.
Publicado: (2012)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas
por: Martinho, O, et al.
Publicado: (2009)

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
por: Dotan, E, et al.
Publicado: (2012)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
por: Martin, V, et al.
Publicado: (2013)

Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer
por: Michikawa, C, et al.
Publicado: (2011)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways
por: Tiwary, R, et al.
Publicado: (2011)

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma
por: Sunaga, N, et al.
Publicado: (2014)

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
por: Gonzalez de Castro, D, et al.
Publicado: (2012)

Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study
por: Horsch, M, et al.
Publicado: (2009)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

Endostatin expression in a pancreatic cell line is modulated by a TNFα-dependent elastase
por: Brammer, R D, et al.
Publicado: (2005)

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
por: Deschoolmeester, V, et al.
Publicado: (2010)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology
por: Ursin, G, et al.
Publicado: (2005)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
por: Renaud, Stéphane, et al.
Publicado: (2015)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease
por: Clark, S E, et al.
Publicado: (2011)

Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
por: Morrison, D H, et al.
Publicado: (2012)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Poly(A) RT–PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer
por: Oliveira-Cunha, M, et al.
Publicado: (2011)

Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype
por: Van der Auwera, I, et al.
Publicado: (2010)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Endostatin expression in pancreatic tissue is modulated by elastase
por: Brammer, R D, et al.
Publicado: (2005)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
por: Saridaki, Z, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8vdul4tbd8b60rsmv27ofh5jhc